Nocira’s Eponymous Acute Migraine Treatment Designated an FDA Breakthrough Device

The FDA has designated Tempe, Ariz.-based Nocira’s acute migraine treatment a Breakthrough Device for use by individuals aged 18 and older.

The drug-free device uses controlled puffs of air in the ears to treat migraine attacks.

The breakthrough designation was supported by positive results from a 59-patient placebo-controlled study.

Twenty minutes after treatment with either Nocira's device or a sham version, 60 percent of those treated with the genuine device had no pain vs. 7 percent of those treated with the placebo, the company said.